Sarepta Falls as FDA Plans to Investigate Death of Child Who Received Elevidys

Sarepta falls as FDA plans to investigate death of child who received Elevidys

#Sarepta Therapeutics Under Scrutiny as ELEVIDYS Investigation Unfolds Amid Financial Challenges

In the world of biopharmaceuticals, the intersection of innovative therapies and robust financial health is critical for sustained growth and development. Recent developments at Sarepta Therapeutics, a leader in precision genetic medicine, particularly in the treatment of rare diseases such as Duchenne muscular dystrophy (Duchenne), present a complex narrative that both captivates the industry and raises significant concerns. 'ELEVIDYS Under Inv…

Sarepta Addresses FDA Investigation: ELEVIDYS Gene Therapy Death Ruled Unrelated to Treatment

Latest update on FDA's investigation into Duchenne therapy ELEVIDYS reveals key safety findings. Sarepta provides crucial clarification on patient case. Get details.

The Deadly Saga of the Controversial Gene Therapy Elevidys

(MIT Technology Review) – It has been a grim few months for the Duchenne muscular dystrophy (DMD) community. There had been some excitement when, a couple of years ago, a gene therapy for the disorder was approved by the US Food and Drug Administration for the first time. That drug, Elevidys, has now been implicated in the deaths of two teenage boys. The drug’s approval was always controversial—there was a lack of evidence that it actually worke…